Has Russell Gollard, MD received payments from drug or device companies?

Yes. Drug and device makers reported $306,968 in general payments to Russell Gollard, MD across 615 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Russell Gollard, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Russell Gollard, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Russell Gollard, MD

Hematology & Oncology · Henderson, NVNPI 1699772210

Payments from drug & device makers

$306,968in general payments, 2019–2025

Across 615 payments — averaging $499.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Merck$91K
Morphosys AG$59K
AstraZeneca$38K
Sobi, Inc$26K
Janssen Research & Development, LLC$12K
Sanofi US Services Inc.$11K
plus $69K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Merck	11	$91,008
Morphosys AG	8	$59,320
AstraZeneca(2 entities)	41	$38,420
Sobi, Inc	24	$26,241
Janssen Research & Development, LLC	1	$11,500
Sanofi US Services Inc.	2	$11,480
EMD Serono, Inc.	16	$8,354
Mirati Therapeutics, Inc.	5	$6,190
Bristol Myers Squibb	21	$5,112
Syndax Pharmaceuticals, Inc.	10	$4,774
Incyte Corporation	12	$3,435
Morphosys, US Inc.	4	$2,932
Epizyme, Inc.	3	$2,917
Novocure Inc.	3	$2,704
Springworks Therapeutics, Inc.	2	$2,514
Eisai Inc.	11	$2,006
CTI Biopharma Corp.	1	$1,950
GSK	5	$1,922
Novartis	43	$1,778
Karyopharm Therapeutics Inc.	8	$1,699
Exelixis Inc.	23	$1,542
Blueprint Medicines Corporation	1	$1,512
Amgen	79	$1,475
Jazz Pharmaceuticals Inc.	1	$1,400
Rigel Pharmaceuticals, Inc.	5	$1,359
Coherus Oncology, Inc.	1	$1,350
Athenex Pharmaceutical Division, LLC	1	$1,250
Daiichi Sankyo Inc.	31	$1,061
Avyxa Pharma, LLC	1	$1,000
Astrazeneca UK Limited	1	$820
Deciphera Pharmaceuticals Inc.	2	$774
Pfizer	31	$639
Johnson & Johnson(2 entities)	22	$605
E.r. Squibb & Sons, L.L.C.	21	$579
Lilly USA, LLC	5	$563
Secura Bio, Inc.	5	$496
Regeneron Healthcare Solutions, Inc.	15	$479
Pharmacyclics LLC, An Abbvie Company	7	$360
Sanofi	10	$358
Seagen Inc.	9	$337
Gilead(2 entities)	17	$319
Astellas Pharma US Inc	12	$313
Genentech USA, Inc.	18	$239
Janssen Scientific Affairs, LLC	2	$176
Foundation Medicine, Inc.	4	$163
Sanofi-aventis U.S. LLC	2	$157
Penumbra, Inc.	1	$143
Caris MPI, Inc.	2	$128
AbbVie	3	$115
Regeneron	1	$107
Bayer	6	$101
Myovant Sciences Inc.	4	$81
Agios Pharmaceuticals, Inc.	2	$77
Clovis Oncology, Inc.	8	$75
Octapharma USA, Inc.	3	$60
Dendreon Pharmaceuticals LLC	3	$51
Boehringer Ingelheim	2	$46
Collegium Pharmaceutical, Inc.	3	$39
Teva Pharmaceuticals USA, Inc.	3	$37
Ipsen Biopharmaceuticals, Inc	2	$35

How this compares

$306,968 in reported general payments places this provider in the 80th percentile of 82 hematology & oncology providers in Nevada.

See all hematology & oncology providers in Nevada →

Medicare billing

Part B allowed, 2024

$2,287,895

Medicare patients

412

Services billed

77,902

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Henderson

Stephani ChristensenHenderson$4.9M
Anthony NguyenHenderson$1M
Regan HoldridgeHenderson$528K
Resty TibayanHenderson$318K
Rupesh ParikhHenderson$192K
Ramalingam RatnasabapathyHenderson$161K
James SanchezHenderson$84K
Gilbert NyamuswaHenderson$33K
Mary Ann AllisonHenderson$11K
Nutan ParikhHenderson$10K

See the full list for Nevada →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →